Why Is PULSE BIOSCIENCES IN (PLSE) Stock Down Today?
By the Top Tier Newswire AI Desk · September 16, 2026 at 10:08 AM ET · reviewed against 3 wire stories
PULSE BIOSCIENCES IN (PLSE) is down -9.00% in the latest session. Our newswire has captured 3 stories on PLSE across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Pulse Biosciences Inc. stock fell 9.00% to $50.23 in morning trade on Monday. The decline followed the company’s filing of two SEC Form 8-K disclosures on Saturday and Sunday. These filings included updates on a material definitive agreement and the completion of enrollment in its PRECISE-BTN clinical study, which may have raised uncertainty among investors.
What Happened
The first 8-K filing on September 15 disclosed the entry into and termination of a material definitive agreement under Items 1.01 and 1.02. The second filing noted other events under Item 8.01. Separately, Pulse Biosciences announced that it completed enrollment in the PRECISE-BTN clinical trial for its nPulse™ Vybrance™ system, with the first patient completing a 12-month follow-up in August. The company said full data will be available once all patients complete follow-up. These updates may have prompted a reassessment of the stock’s risk profile and growth potential.
What The Data Shows
PLSE opened at $55.58, a 0.7% gap up from the prior close, but quickly fell to a session low of $50.01. The stock traded at $50.10 at the time of the report, with volume at 0.1 million shares, or 0.2 times the 3-month daily average. The stock has a market cap of $3.9 billion, a beta of 1.62, and a 52-week range of $12.56 to $58.90. Recent insider activity includes two purchases by COO Liane Rae Teplitsky totaling $200,000 in the last five days. The 52-week tape also showed two new 52-week highs and five new 52-week lows on September 16.
What To Watch
The company has not announced an upcoming earnings date. Investors should monitor the full data release from the PRECISE-BTN study and any follow-up commentary from management.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
PLSE · today's session (5-min) · -10.15% vs prior close · updated 3:46 PM ETAI sentiment, last 36h · averaged over 3 stories · 53/100 neutral
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
23h agoSEC 8-KNEUTRAL 50General
PULSE BIOSCIENCES, INC. (PLSE) files 8-K
Filed: 2026-09-15 AccNo: 0001437749-26-030456 Size: 415 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
1d agoSEC 8-KNEUTRAL 50General
PULSE BIOSCIENCES, INC. (PLSE) files 8-K
Filed: 2026-09-15 AccNo: 0001437749-26-030392 Size: 172 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
1d agoStockTitanBULLISH 59Product/PR
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
The first patient finished 12-month follow-up in August; enrollment spanned three U.S. sites, with full data expected after all patients complete follow-up.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →